ATE331026T1 - Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel - Google Patents

Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel

Info

Publication number
ATE331026T1
ATE331026T1 AT95927611T AT95927611T ATE331026T1 AT E331026 T1 ATE331026 T1 AT E331026T1 AT 95927611 T AT95927611 T AT 95927611T AT 95927611 T AT95927611 T AT 95927611T AT E331026 T1 ATE331026 T1 AT E331026T1
Authority
AT
Austria
Prior art keywords
pct
gene product
hiv
antigenic marker
marker
Prior art date
Application number
AT95927611T
Other languages
English (en)
Inventor
Benjamin Rovinski
Shi-Xian Cao
Fei-Long Yao
Roy Persson
Michel H Klein
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE331026T1 publication Critical patent/ATE331026T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/00022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
AT95927611T 1994-08-15 1995-08-15 Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel ATE331026T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/290,105 US5955342A (en) 1994-08-15 1994-08-15 Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region

Publications (1)

Publication Number Publication Date
ATE331026T1 true ATE331026T1 (de) 2006-07-15

Family

ID=23114550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95927611T ATE331026T1 (de) 1994-08-15 1995-08-15 Antigen-markierte nicht-infektiöse retrovirus- ähnlige partikel

Country Status (12)

Country Link
US (5) US5955342A (de)
EP (1) EP0778888B1 (de)
JP (2) JP3871708B2 (de)
AT (1) ATE331026T1 (de)
AU (1) AU704309B2 (de)
CA (1) CA2197446A1 (de)
DE (1) DE69535075T2 (de)
DK (1) DK0778888T3 (de)
ES (1) ES2268693T3 (de)
MX (1) MX9701149A (de)
PT (1) PT778888E (de)
WO (1) WO1996005292A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6080408A (en) * 1994-08-22 2000-06-27 Connaught Laboratories Limited Human immunodeficiency virus type 1 nucleic acids devoid of long terminal repeats capable of encoding for non-infectious, immunogenic, retrovirus-like particles
CA2202761A1 (en) 1994-10-18 1996-04-25 Sean Nicholas Chapman Method of producing a chimeric protein
EP0817854A2 (de) * 1995-03-31 1998-01-14 Wolf, Hans, Prof. Dr. Verfahren zur antigenpräsentation, aufbauend auf retrovirusähnlichen partikeln
GB9607899D0 (en) * 1996-04-17 1996-06-19 Scottish Crop Research Inst Virus-like particle
US6602505B2 (en) * 1998-04-30 2003-08-05 University Of Southern California Viral chimeras comprised of CAEV and HIV-1 genetic elements
EP1078105B1 (de) 1998-05-12 2004-11-24 Genecure LLC Replikationsdefekter hiv impfstoff
JP4776075B2 (ja) * 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7935805B1 (en) * 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6534064B1 (en) * 1999-10-13 2003-03-18 Chiron Corporation Stabilized protein particles for inducing cellular immune responses
US8623379B2 (en) * 2000-03-02 2014-01-07 Emory University Compositions and methods for generating an immune response
WO2002072754A2 (en) * 2001-03-08 2002-09-19 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mva expressing modified hiv envelope, gag, and pol genes
US20040105871A1 (en) * 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
AU2002211948B2 (en) 2000-03-02 2007-09-13 Emory University DNA expression vectors and methods of use
WO2002000169A2 (en) * 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agriculture Production of vaccines using transgenic plants
AU2001287103B2 (en) * 2000-09-09 2007-02-01 Intervet International B.V. EIAV chimeric vaccine and diagnostic
US6461616B1 (en) * 2000-09-09 2002-10-08 Akzo Nobel Nv EIAV p26 deletion vaccine and diagnostic
US7122180B2 (en) * 2000-10-23 2006-10-17 Children's Medical Center Corporation DNA vectors containing mutated HIV proviruses
EP1201750A1 (de) * 2000-10-26 2002-05-02 Genopoietic Synthetische Viren und ihre Verwendungen
WO2003004657A1 (en) * 2001-07-05 2003-01-16 Chiron Corporation Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof
AU2002320314A1 (en) 2001-07-05 2003-01-21 Chiron, Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
WO2003020876A2 (en) * 2001-08-31 2003-03-13 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
WO2003077838A2 (en) * 2002-03-05 2003-09-25 National Institutes Of Health Office Of Technology Transfer Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
EP1581256A4 (de) * 2002-11-14 2006-06-07 Pfizer Prod Inc Verwendung von rmlt als marker-antigen für vakzine und als synergistisches adjuvans mit amphigen
CA2637600A1 (en) 2006-01-17 2007-07-26 Health Research, Inc. Heteroduplex tracking assay
EP2152730A4 (de) * 2007-05-02 2011-08-03 Univ Emory Erweiterung der glycoproteininkorporation in virusähnlichen partikeln
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
DK2691530T3 (en) 2011-06-10 2018-05-22 Univ Oregon Health & Science CMV GLYCOPROTEIN AND RECOMBINANT VECTORS
EP2568289A3 (de) 2011-09-12 2013-04-03 International AIDS Vaccine Initiative Immunselektion von rekombinantem vesikulärem Stomatitisvirus mit Expression von HIV-1-Proteinen durch Breitbandneutralisierungs-Antikörper
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3069730A3 (de) 2015-03-20 2017-03-15 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5352449A (en) * 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
EP0496794A1 (de) * 1989-10-16 1992-08-05 Whitehead Institute For Biomedical Research Nichtinfektiöse partikeln von hiv-1 und verwendungen davon
CA2068713A1 (en) * 1989-11-20 1991-05-21 Omar K. Haffar Non-replicating recombinant-made retroviral particles used as antiviral agents and immunogens
WO1991019803A1 (en) * 1990-06-19 1991-12-26 Applied Biotechnology, Incorporated Self assembled, defective, nonself-propagating viral particles
JPH08500005A (ja) * 1992-03-27 1996-01-09 ホワイトヘッド インスティチュート フォー バイオメディカル リサーチ 非感染性ｈｉｖ粒子およびその用途
AU4685293A (en) * 1992-07-20 1994-02-14 Immune Response Corporation, The Prophylactic and therapeutic control of retroviral infections
GB9412844D0 (en) * 1994-06-27 1994-08-17 Medical Res Council Improvements in or relating to therapeutic methods

Also Published As

Publication number Publication date
EP0778888B1 (de) 2006-06-21
EP0778888A1 (de) 1997-06-18
US5879925A (en) 1999-03-09
US6025125A (en) 2000-02-15
ES2268693T3 (es) 2007-03-16
US5889176A (en) 1999-03-30
DK0778888T3 (da) 2006-10-23
US5955342A (en) 1999-09-21
WO1996005292A1 (en) 1996-02-22
CA2197446A1 (en) 1996-02-22
DE69535075T2 (de) 2007-01-04
JP3871708B2 (ja) 2007-01-24
US5866320A (en) 1999-02-02
AU3159995A (en) 1996-03-07
DE69535075D1 (de) 2006-08-03
MX9701149A (es) 1997-05-31
JP2006020635A (ja) 2006-01-26
PT778888E (pt) 2006-11-30
AU704309B2 (en) 1999-04-22
JPH10503933A (ja) 1998-04-14

Similar Documents

Publication Publication Date Title
DE69535075D1 (de) Antigen-markierte nicht-infektiöse retrovirus-ähnlige partikel
Gherardi et al. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes
Osterhaus et al. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom.
Bonsignori et al. HIV-1 envelope induces memory B cell responses that correlate with plasma antibody levels after envelope gp120 protein vaccination or HIV-1 infection
DE69535757D1 (de) Rekombinanter immunschwächepoxvirus
SE8701413L (sv) Expression och rening av en htlv-iii gag/env-gen protein
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
ID30497A (id) Peptida hiv, antigen, komposisi vaksin, kit imunoasai dan metoda untuk mendeteksi antibodi yang diinduksi oleh hiv
ATE153071T1 (de) Neue proteinhaltige partikeln
ATE36956T1 (de) Verfahren zu herstellung von lebenden, adjuvierten impfstoffen und so erhaltende lebende, adjuvierte impfstoffe.
ES2066887T3 (es) Anticuerpo monoclonal para diferenciar individuos seropositivos hiv-2 de los hiv-1.
EP0433242A1 (de) Impfstoffe und Verfahren zu deren Herstellung
Verrier et al. A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates
DK0880360T3 (da) Hidtil ukendte fremgangsmåder til vaccination og vacciner dertil, hvilke vacciner omfatter en nucleinsyre, der koder en første epitop, og et peptid, der indeholder en sekundær epitop
EA200300335A1 (ru) Регуляторные и вспомогательные пептиды вич, антигены, вакцинные композиции, набор для иммуноанализа и способ обнаружения антител, индуцируемых вич
EP1013757A3 (de) Abgeschwächte Formen des Rinderdiarrhöevirus
Merza et al. Bovine leukaemia virus ISCOMs: biochemical characterization
IL86675A (en) Immunogen containing non- infectious hiv particles and pharmaceutical compositions containing the same
Åkerblom et al. Formation and characterization of FeLV ISCOMs
Pincus et al. Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.
KR960705919A (ko) 제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain)
Höglund et al. Characterization of immunostimulating complexes (ISCOMs) of HIV-1
US5830476A (en) Active induction or passive immunization of anti-Gp48 antibodies and isolated gp48 protein
Zimmerman et al. Cross-clade p17 peptide recognition by antisera to HGP-30, a 30-amino acid synthetic peptide antigen from HIV type 1 p17
Krohn et al. Proliferative T‐Cell Response to HIV Envelope Glycoprotein in Immunized and Infected Primates and Human Beings

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0778888

Country of ref document: EP